ImmunoGen Gets Positive Data on New Drug

In this volatile market, investors need stocks that will keep them interested even when things are at their most bleak, says Mad Money host, Jim Cramer. Discussing the next-generation of cancer treatments with biotech developer, Daniel Julies, ImmunoGen CEO.
00:00
Mon, Sep 26 20116:48 PM EST